Targeted support for science and research and a long-term commitment to improving life in our society. These are the main points of our newly established collaboration with the international research institute, INDRC, founded by the leading Czech neurologist and scientist Martin Tolar. The institute’s research specialises in a wide range of neurodegenerative diseases, including Alzheimer’s disease, which more than 160,000 people in the Czech Republic suffer from. Martin Tolar’s American company Alzheon is currently working on a cure for this disease in Boston. The results of the clinical studies are very promising.
We have been following the non-profit research institute INDRC (International Neurodegenerative Disorders Research Center) and its activities with great interest since it was founded in 2021. In September 2022, we participated in a quite unique scientific conference in Prague that brought together and connected the most prominent neurologists involved in the research and treatment of Alzheimer’s disease and other associated neurodegenerative diseases with researchers focusing on artificial intelligence. The whole event was attended by leading neuroscientists from prestigious European and American universities, ML (machine learning) experts and AI (artificial intelligence) specialists, with the aim of accelerating the processing of data about the brain and its disorders and using the output for further research into Alzheimer’s. The ultimate objective is to find a functional diagnosis, treatment and prevention of the disease in the shortest possible time.
The conference in Prague marked the start of an intensive collaboration among experts who now come together at regular scientific meetings organised by INDRC and share their experiences from previous scientific projects and shape the directions of new projects run by INDRC and other institutions and their collaborators.
“I am so pleased that I can be “at the birth” of so many great thoughts and ideas from members of the INDRC Scientific Advisory Board and to observe at regular meetings their sincere commitment to seeking and finding new ways of scientific research using modern technologies. The objective is to come up with new and unprecedented innovative approaches leading to the treatment of neurodegenerative diseases,” says Lenka Uldrijanová, Executive Director of INDRC.
“The team of experts associated with INDRC is doing extraordinary work, and their findings mean that there is hope for hundreds of thousands, perhaps millions of patients suffering from various neurodegenerative diseases. I had the privilege of meeting Martin Tolar in the early days of the institute. His specialist knowledge and the enthusiasm with which he goes about researching a cure for Alzheimer’s disease is truly inspirational. I am incredibly pleased that Progesus can give financial support to the advancement of this field which signifies great hope and also an incredible development in the scientific capabilities of mankind,” says Lukáš Foral, co-owner of Progesus.
Alzheimer’s disease is a neurodegenerative disease manifested by a loss of nerve cells in certain parts of the brain. The disease is the most common cause of dementia, which occurs in various forms in more than 7 million people in Europe. According to educated estimates by Alzheimer’s Disease International (ADI), in 2013 around 35 million people worldwide required long-term care. There is currently no effective cure for the disease, but this could change due to the work being done by a team of scientists led by Martin Tolar at his company Alzheon. The research team has already completed several successful phases of clinical trials of a miracle drug. The team is currently in the final phase of trials and the results are looking very promising.
We are very pleased that through our partnership with INDRC we can help develop scientific knowledge in this field, which means a hopeful and healthier future for us all.